Molecure reçoit une recommandation favorable de l’IDMC pour poursuivre l’essai clinique KITE sans modification du protocole de l’étude (programme de développement OATD-01)

Phase 2positiveOATD-01Positive

AI Analysis

Summary

Molecure received a favorable recommendation from the Independent Data Monitoring Committee to continue the Phase II KITE trial of OATD-01, a first-in-class CHIT1 inhibitor, in patients with active pulmonary sarcoidosis without protocol modifications.

Clinical Trial Data

Phase

Outcome Details

IDMC recommended continuation of KITE Phase II clinical trial without protocol modifications

Importance:6/10

Sentiment:

0.70

Phase 2clinical trialIDMC reviewOATD-01sarcoidosisCHIT1 inhibitor

Related Companies

$ACTI.ST $GILD

Read the original article

Published by GlobeNewswire Clinical Studies on August 4, 2026 2:04 PM

Read Original